Cargando…

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure

BACKGROUND: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of SGLT2i on renal function and outcome remains uninvestigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagaito, Masaki, Imamura, Teruhiko, Joho, Shuji, Ushijima, Ryuichi, Nakamura, Makiko, Kinugawa, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296582/ https://www.ncbi.nlm.nih.gov/pubmed/34289813 http://dx.doi.org/10.1186/s12872-021-02163-7

Ejemplares similares

Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2022)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2023)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021)

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
por: Nakamura, Makiko, et al.
Publicado: (2023)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Association between Remote Dielectric Sensing and Estimated Plasma Volume to Assess Body Fluid Distribution
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Correlation between Remote Dielectric Sensing and Chest X-Ray to Assess Pulmonary Congestion
por: Izumida, Toshihide, et al.
Publicado: (2023)

Urinary Isoxanthopterin in Heart Failure Patients
por: Hori, Masakazu, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis
por: Morita, Hiroyasu, et al.
Publicado: (2022)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
por: Takata, Tomoaki, et al.
Publicado: (2021)

Therapeutic Strategy for Patients with Concomitant Pulmonary Artery Hypertension and Hypertrophic Obstructive Cardiomyopathy: A Rare Case Report
por: Izumida, Toshihide, et al.
Publicado: (2023)

Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients With Acute Decompensated Heart Failure
por: Matsukawa, Ryuichi, et al.
Publicado: (2023)

Bail-out Ablation of Ventricular Tachycardia Electrical Storm in a Patient with a Durable Left Ventricular Assist Device
por: Izumida, Toshihide, et al.
Publicado: (2022)

Combination Treatment of Balloon Pulmonary Angioplasty and Direct Oral Anticoagulant in a Patient with Chronic Thromboembolic Pulmonary Hypertension Complicated by Protein S Deficiency
por: Izumida, Toshihide, et al.
Publicado: (2023)

A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
por: Post, Adrian, et al.
Publicado: (2020)

Renoprotective effect of additional sodium–glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function
por: Sada, Kentaro, et al.
Publicado: (2022)

Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure
por: Hori, Masakazu, et al.
Publicado: (2020)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

A Young Patient Presenting with Atrioventricular Block Diagnosed as Myotonic Dystrophy
por: Onoda, Hiroshi, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
por: Griffin, Matthew, et al.
Publicado: (2020)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2016)

Successful Conversion from Conventional Potassium Binder to Sodium Zirconium Cyclosilicate in a Patient with Refractory Constipation
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure
por: Fukuda, Nobuyuki, et al.
Publicado: (2022)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Impact of the Severity of Acquired von Willebrand Syndrome on the Short-Term Prognosis in Patients with Temporary Mechanical Circulatory Support
por: Nakamura, Makiko, et al.
Publicado: (2022)

Pulmonary Artery Pulsatility Index and Hemolysis during Impella-Incorporated Mechanical Circulatory Support
por: Nakamura, Makiko, et al.
Publicado: (2022)

Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis
por: Izumida, Toshihide, et al.
Publicado: (2021)

Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes
por: Yokouchi, Go, et al.
Publicado: (2022)

Initial report of percutaneous left atrial appendage closure in hemodialysis patients with atrial fibrillation and high risk of bleeding in Japan
por: Ueno, Hiroshi, et al.
Publicado: (2022)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Angiopoietin‐2 and hemocompatibility‐related adverse events during percutaneous left ventricular assist device supports
por: Imamura, Teruhiko, et al.
Publicado: (2020)

Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
por: Hida, Yuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qe0e8uv4pip5g2d8l0kn6dsj9k